← Eichor
Condition: Transthyretin Mediated Amyloidosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Transthyretin Mediated Amyloidosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Phase N/A · 40 location(s) · Alnylam Pharmaceuticals · NCT04561518TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos
Phase 3 · 41 location(s) · Alnylam Pharmaceuticals · NCT07223203TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Phase 3 · 240 location(s) · Alnylam Pharmaceuticals · NCT07052903A Phase 3 Study of NTLA-2001 in ATTRv-PN
Phase 3 · 14 location(s) · Intellia Therapeutics · NCT06672237MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Phase 3 · 132 location(s) · Intellia Therapeutics · NCT06128629DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
Phase N/A · 4 location(s) · Alnylam Pharmaceuticals · NCT07358078Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Phase N/A · 82 location(s) · AstraZeneca · NCT06465810Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Phase N/A · 7 location(s) · Alnylam Pharmaceuticals · NCT05040373
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.